We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Selexis SA and Hoba Therapeutics announced today that they have entered into an agreement to advance the development of Hoba’s clinical candidate HB-086 (rhMeteorin) for the treatment of peripheral neuropathic pain.